IMMUNO-ONCOLOGY PREDICTIVE ASSAY
Currently, Magellan Bioanalytic's primary research focus is leveraging its COMPASS technology to identify biomarker profiles that predict patient response to immunotherapy (IO), making sure patients receive the right treatment and minimizing waste of healthcare resources.